Patents by Inventor Gaetan Otto
Gaetan Otto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220064740Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: September 15, 2021Publication date: March 3, 2022Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 11149317Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: October 8, 2018Date of Patent: October 19, 2021Assignee: Exact Sciences Development Company, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 10808286Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: May 4, 2018Date of Patent: October 20, 2020Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20190032149Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: October 8, 2018Publication date: January 31, 2019Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20180327859Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: May 4, 2018Publication date: November 15, 2018Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 9982308Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: February 4, 2015Date of Patent: May 29, 2018Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20150240318Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging, or otherwise characterizing various diseases.Type: ApplicationFiled: February 4, 2015Publication date: August 27, 2015Applicant: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Patent number: 8969046Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: January 9, 2008Date of Patent: March 3, 2015Assignee: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20120039993Abstract: An oligonucleotide, primer or probe comprises the nucleotide sequence of any of SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 61, 62 or 63. The oligonucleotide, primer or probe is useful for the detection of the methylation status of a gene. The oligonucleotides find application in the diagnosis and treatment of cancer.Type: ApplicationFiled: March 17, 2010Publication date: February 16, 2012Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, MDXHEALTH SAInventors: Gaetan Otto, Catherine Bovie
-
Publication number: 20100144836Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, 11112, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: January 9, 2008Publication date: June 10, 2010Applicant: ONCOMETHYLOME SCIENCES SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning